title: Secondary antifungal prophylaxis in pediatric hematopoietic stem cell transplants.
abstract: Invasive fungal infections (IFIs) constitute a leading cause of morbidity and infection-related mortality among hematopoietic stem cell transplant (HSCT) recipients. With the use of secondary prophylaxis, a history of IFI is not an absolute contraindication to allo-HSCT. However, still, IFI recurrence remains a risk factor for transplant-related mortality. In this study, of the 105 children undergoing HSCT between April 2010 and February 2013, 10 patients who had IFI history before transplantation and had undergone allo-HSCT were evaluated retrospectively to investigate results of secondary prophylaxis. In conclusion, our study shows that amphotericin B and caspofungin was successful as secondary antifungal prophylaxis agents with no relapse of IFI. In addition, after engraftment, secondary prophylaxis was continued with voriconazole orally in 4 patients that yielded good results.
authors.affiliation: *Pediatric Hematology Unit ‡Pediatric Infectious Disease Unit, Ankara Hematology Oncology Children's Training and Research Hospital †Gazi University Faculty of Medicine Pediatric Infectious Diseases Unit, Ankara, Turkey.
authors.forename: Fatih M
authors.initials: FM
authors.lastname: Azik
authors.forename: Hasan
authors.initials: H
authors.lastname: Tezer
authors.forename: Aslinur
authors.initials: A
authors.lastname: Ozkaya-Parlakay
authors.forename: Tekin
authors.initials: T
authors.lastname: Aksu
authors.forename: Cengiz
authors.initials: C
authors.lastname: Bayram
authors.forename: Ali
authors.initials: A
authors.lastname: Fettah
authors.forename: Betül
authors.initials: B
authors.lastname: Tavil
authors.forename: Bahattin
authors.initials: B
authors.lastname: Tunç
mesh_terms: D000293:Adolescent; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D000077336:Caspofungin; D002648:Child; D054714:Echinocandins / Q000627:therapeutic use; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D055666:Lipopeptides; D008297:Male; D009181:Mycoses / Q000517:prevention & control*; D012189:Retrospective Studies
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000666:Amphotericin B; D000077336:Caspofungin